Patients hospitalized with influenza and treated with oseltamivir on the day of admission were less likely to experience severe clinical outcomes compared with those who were treated later, researchers found.
“Randomized clinical trials that can evaluate the benefit of antiviral treatment for hospitalized influenza patients (vs. no treatment) are rare and difficult to execute. In addition, we know that the timing of treatment is an important factor in achieving the greatest benefit from these medications,” Nathaniel M. Lewis, PhD, Epidemic Intelligence Service (EIS) officer with CDC’s